Status:
COMPLETED
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants Above 19 Years of Age With Acute Myeloid Leukemia (AML)
Lead Sponsor:
AbbVie
Conditions:
Acute Myeloid Leukemia (AML)
Eligibility:
All Genders
19+ years
Brief Summary
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections). This study will assess how safe and effective oral venetoclax i...
Eligibility Criteria
Inclusion
- -Acute Myeloid Leukemia (AML) participants who have been prescribed oral Venetoclax tablets for the first time according to the approved label.
Exclusion
- Participants with contraindications to Venetoclax as listed on the approved local label.
- Participants receiving Venetoclax in clinical trials.
Key Trial Info
Start Date :
April 5 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 20 2025
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04826523
Start Date
April 5 2021
End Date
October 20 2025
Last Update
November 26 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Pusan National University Hospital /ID# 239010
Busan, Busan Gwang Yeogsi, South Korea, 49241
2
Kosin University Gospel Hospital /ID# 257399
Busan, Busan Gwang Yeogsi, South Korea, 49267
3
Kyungpook National University Hospital /ID# 257398
Daegu, Daegu Gwang Yeogsi, South Korea, 41944
4
Gachon University Gil Medical Center /ID# 239008
Incheon, Gyeonggido, South Korea, 21565